you, Thank Tom.
X Our growth strategy is built elements. core on
Medicare DPNCheck is organic first Advantage The the growth in business.
addressable to indication market, additional advance the market. which to establish expanded the comment Quell program, Quell I and and in the will grow lead each Fibromyalgia an of neurotherapeutics to these activities. is the The third may U.S. second indications on and is
First, to with DPNCheck. respect
peripheral or is study a diabetic point-of-care a such neuropathies is complication peripheral gold as for nerve reminder, based rapid which DPNCheck the DPNCheck on standard test neuropathy the DPN, point-of-care test technology. of most conduction only diabetes. peripheral neuropathy, is As common long-term
primarily DPNCheck domestic Our international of revenue Medicare business-to-business of sales in XX% and business and to into comes is through sales comprised distribution partners. market, Advantage U.S. the China Japan DPNCheck from XX% sales.
systems Advantage a years. focused where substantial assessment companies, value-based team the in business over This has Medicare groups, their care adoption been IDNs, Advantage. commercial under the large are patients market. We of a several past on This portion growing health DPNCheck increasing and medical includes covered Medicare have health
and in sector X Advantage the into due by first substantial past Medicare & Services, announced changes to Medicaid uncertainty for year, this of However, Centers quarter injected CMS. months, the policy or Medicare the the in in particular was
improper January risk Advantage Risk On Advantage adjustment Data Medicare RADV Medicare XX to CMS a rule issued recover Adjustment to payments this program, used also of final the regarding that is year, Validation, risk February XXXX this X CMS on Medicare issued calendar then hierarchical HCC, to And Advantage significant its for model condition XXXX. of year included which adjustment notice, categories, advanced plans. the year, changes called
environment have in by for this to factors suspend customer was be may Advantage detected adopted and are and influenced including proposal uncertainty that of largest early phased April that Medicare We DPNCheck that will Medicare over programs. and DPNCheck. The X includes believe HCC model programs, the swinging limitation next other our in many related neuropathies peripheral their alters announced codes CMS risk new years. on the the adjustment
to premise peripheral At if of and will ulcers, essential a is common and reduce DPNCheck we DPNCheck, this fundamental early to behind falls, costs. detection that the debilitating Nevertheless, debilitating health time, permanent continue in the diabetic or customers clinical majority this and that accurate which a know with condition overall not that the decision. is including we temporary is embrace neuropathic do is to our elderly and neuropathy complications, minimize pain care believe foot
our and to fundamental not this product changes development made commercial At time, strategies. have we
later the next into and moving certain However, year. may evolving year this are evaluating we landscape adaptations make and
regularly encouraged support continued We our decision as to But the are for the And their as the clinical need environment. new to heard programs DPNCheck their adjustment modify these risk have customers screening screening clinical the they to adjust programs of by for with we the reflect patients. we right new environment. speaking also are
sum total The changes predict. of these difficult is Advantage to our DPNCheck business Medicare on
We DPNCheck expect that on put they downward pressure will material revenues.
impact. of business cash However, of and determine will DPNCheck flow it is the magnitude the positive early virtue we that the expect too to operating to continue generate line margins. by duration attractive its Nevertheless,
of potential we once there that a resumed get uncertainty. growth believe for also is We this through period
the often unmet by platform, chronic pain, the Fibromyalgia many syndrome The our proprietary effects. only. XX milnacipran, in Fibromyalgia. Quell a pregabalin, indicated are of treatments. to based a this There available authorization is nerve pain fibromyalgia. Novo time, is and on substantial U.S. recently transcutaneous help that FDA De stimulation of symptoms electrical is have duloxetine our This latter the first complex focused drugs affects side people for prescription fibromyalgia At device additional only only exclusively critical wearable as It indication. indication neuromodulation which safe commercialization Moving are is need cleared for which is FDA-approved lower a on efforts as is million as Quell the received chronic and FDA to extremity reduce medical relief adaptive on technology. and
prescription collect commercial of small optimize solution year December Fibromyalgia last follow to did processing this of amount the was of This first our full of quarter launch Quell of key that effectiveness and the of to year. and phase is marketing the to and activity indicators. the QX clinical strategic a in messaging refine performance initial intended
commercial National at of a single Our consists is Sales. which this Director headcount, team of time dedicated our
Fibromyalgia consists initial a of fill device consists online electrodes cash-pay and basis. X of pharmacy available is a electrodes. on refills, of We At which X a have of partnered prescriptions, with and time, national this months which to both month Quell
early will of this commercialization, provide and number business, of stage prescriptions At the on would written top-of-the-funnel what the call prescribers. we of the number metrics specifically we
for conversion prescriptions the prescriptions matures, reporting metrics example, that As we characterize of percentage are the consider business that written to will of revenue, additional filled.
by neurologists care pain Through includes of end this year, been first primary the this of physicians. different specialists, and rheumatologists, XXX written XX have the medicine and prescriptions quarter prescribers,
that which launch, intend we Our have reliable methodical commercial and a entail robust not indicators. size estimates few investment. commercial continuing the of understanding in a from performance key relevant while to Fibromyalgia the will We team time model. we that the We quarters, have and will we next we proceed the market, do is a business a predetermined be of most modestly Quell will confident will the are have full for increase substantial to expectation once to when refine the transition financial
of element our program. third moving is to Quell strategy, Now neurotherapeutics our the on growth which
for the develop CIPN, the element So initial the peripheral program is January effect the breakthrough fibromyalgia indication. along many of effect beyond received in U.S. XXXX moderate be the to debilitating The third in as FDA people treatment. Rochester. be pilot every of is side on neuropathy, approximately cancer chronic which to -- receive that and chemotherapy-induced University can based who of as affects year, XX% CIPN debilitating chronically is can chemotherapy it XXX,XXX conducted the of and a at study or program this furthest severe side treating designation Quell for
late should sham-controlled trial the by late at XXXX our of be of initial multicenter in A and data of is completed If and point. NIH and that indication, end data clinical third be in results supported filing required in a an is represents expected not Institute-funded the prepared to National commercialization to XXXX, are we the for randomized questions CIPN Quell We'd year. this happy Cancer enrollment take with submit then additional XXXX. quarter double-blinded CIPN FDA And potential this Quell positioned comments. by readout
